243 related articles for article (PubMed ID: 26879560)
21. Accuracy of an automated knowledge base for identifying drug adverse reactions.
Voss EA; Boyce RD; Ryan PB; van der Lei J; Rijnbeek PR; Schuemie MJ
J Biomed Inform; 2017 Feb; 66():72-81. PubMed ID: 27993747
[TBL] [Abstract][Full Text] [Related]
22. Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature.
Winnenburg R; Shah NH
BMC Bioinformatics; 2016 Jun; 17():250. PubMed ID: 27333889
[TBL] [Abstract][Full Text] [Related]
23. Transfer of Clinical Drug Data to a Research Infrastructure on OMOP - A FAIR Concept.
Reinecke I; Zoch M; Wilhelm M; Sedlmayr M; Bathelt F
Stud Health Technol Inform; 2021 Nov; 287():63-67. PubMed ID: 34795082
[TBL] [Abstract][Full Text] [Related]
24. Standardizing Austrians Claims Data Using the OMOP Common Data Model: A Feasibility Study.
Haberson A; Rinner C; Gall W
Stud Health Technol Inform; 2019; 258():151-152. PubMed ID: 30942734
[TBL] [Abstract][Full Text] [Related]
25. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.
Reich CG; Ryan PB; Suchard MA
Drug Saf; 2013 Oct; 36 Suppl 1():S195-204. PubMed ID: 24166235
[TBL] [Abstract][Full Text] [Related]
26. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
Carnahan RM; Moores KG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
[TBL] [Abstract][Full Text] [Related]
27. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model.
Makadia R; Ryan PB
EGEMS (Wash DC); 2014; 2(1):1110. PubMed ID: 25848597
[TBL] [Abstract][Full Text] [Related]
28. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries.
Pratt N; Chan EW; Choi NK; Kimura M; Kimura T; Kubota K; Lai EC; Man KK; Ooba N; Park BJ; Sato T; Shin JY; Wong IC; Kao Yang YH; Roughead EE
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):858-64. PubMed ID: 25907076
[TBL] [Abstract][Full Text] [Related]
29. Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM).
You SC; Lee S; Cho SY; Park H; Jung S; Cho J; Yoon D; Park RW
Stud Health Technol Inform; 2017; 245():467-470. PubMed ID: 29295138
[TBL] [Abstract][Full Text] [Related]
30. Predictive modeling of structured electronic health records for adverse drug event detection.
Zhao J; Henriksson A; Asker L; Boström H
BMC Med Inform Decis Mak; 2015; 15 Suppl 4(Suppl 4):S1. PubMed ID: 26606038
[TBL] [Abstract][Full Text] [Related]
31. A two-stage workflow to extract and harmonize drug mentions from clinical notes into observational databases.
Almeida JR; Silva JF; Matos S; Oliveira JL
J Biomed Inform; 2021 Aug; 120():103849. PubMed ID: 34214696
[TBL] [Abstract][Full Text] [Related]
32. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.
Schuemie MJ; Trifirò G; Coloma PM; Ryan PB; Madigan D
Stat Methods Med Res; 2016 Dec; 25(6):2577-2592. PubMed ID: 24685766
[TBL] [Abstract][Full Text] [Related]
33. Guidelines for submitting adverse event reports for publication.
Kelly WN; Arellano FM; Barnes J; Bergman U; Edwards IR; Fernandez AM; Freedman SB; Goldsmith DI; Huang K; Jones JK; McLeay R; Moore N; Stather RH; Trenque T; Troutman WG; van Puijenbroek E; Williams F; Wise RP; ;
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):581-7. PubMed ID: 17471601
[TBL] [Abstract][Full Text] [Related]
34. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection.
Wahab IA; Pratt NL; Wiese MD; Kalisch LM; Roughead EE
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):496-502. PubMed ID: 23412832
[TBL] [Abstract][Full Text] [Related]
35. A Realism-Based View on Counts in OMOP's Common Data Model.
Ceusters W; Blaisure J
Stud Health Technol Inform; 2017; 237():55-62. PubMed ID: 28479543
[TBL] [Abstract][Full Text] [Related]
36. [Benefits of large healthcare databases for drug risk research].
Garbe E; Pigeot I
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Aug; 58(8):829-837. PubMed ID: 26092163
[TBL] [Abstract][Full Text] [Related]
37. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association.
Gruber S; Chakravarty A; Heckbert SR; Levenson M; Martin D; Nelson JC; Psaty BM; Pinheiro S; Reich CG; Toh S; Walker AM
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):973-81. PubMed ID: 27418432
[TBL] [Abstract][Full Text] [Related]
38. Learning predictive models of drug side-effect relationships from distributed representations of literature-derived semantic predications.
Mower J; Subramanian D; Cohen T
J Am Med Inform Assoc; 2018 Oct; 25(10):1339-1350. PubMed ID: 30010902
[TBL] [Abstract][Full Text] [Related]
39. [Drug-induced pancreatitis. A review of French spontaneous reports].
Chebane L; Bagheri H; Hillaire-Buys D; Géniaux H; Yahioui N; Laroche ML; Cottin J; Spreux A; Mosquet B; Pecriaux C; Bellet F; Lambert A; Montastruc JL
Rev Med Interne; 2015 Sep; 36(9):573-8. PubMed ID: 26045335
[TBL] [Abstract][Full Text] [Related]
40. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
